Azad A.A., Eigl B.J., Leibowitz-Amit R., Lester R., Kollmannsberger C., Murray N., Clayton R., Heng D.Y.C., Joshua A.M., Chi K.N.
[Article in Press] European Urology
Background: Although abiraterone acetate (abiraterone) has proven efficacy in two randomised phase 3 trials in metastatic castration-resistant prostate cancer (mCRPC), patients who had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ?2 were either excluded or under-represented in these trials. Objective: To compare outcomes in ECOG PS 0-1 and ?2 in mCRPC patients treated with abiraterone. Design, setting, and participants: Cancer registries from three Canadian centres were used to retrospectively identify mCRPC patients (postdocetaxel and docetaxel-naïve) treated with abiraterone. ECOG PS, clinicopathologic characteristics, prostate-specific antigen (PSA) response, and survival data were collected. Outcome measurements and statistical analysis: Survival outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazards modelling was used to examine the effect of clinicopathologic characteristics on overall survival (OS) and time to PSA progression… (ver más)